Your browser doesn't support javascript.
loading
Priming treatment with T-cell redirecting bispecific antibody ERY974 reduced cytokine induction without losing cytotoxic activity in vitro by changing the chromatin state in T cells.
Iwata, Yoshika; Narushima, Yuta; Harada, Asako; Mishima, Masayuki.
Affiliation
  • Iwata Y; Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan. Electronic address: iwataysk@chugai-pharm.co.jp.
  • Narushima Y; Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan.
  • Harada A; Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan.
  • Mishima M; Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan.
Toxicol Appl Pharmacol ; 441: 115986, 2022 04 15.
Article in En | MEDLINE | ID: mdl-35304238
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: T-Lymphocytes / Antineoplastic Agents Limits: Animals / Humans Language: En Journal: Toxicol Appl Pharmacol Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: T-Lymphocytes / Antineoplastic Agents Limits: Animals / Humans Language: En Journal: Toxicol Appl Pharmacol Year: 2022 Type: Article